key: cord-0840033-y0slnjn0
authors: Choudhury, Y.; Cher, C. Y.; Wan, Z. Y.; Xie, C.; Lim, J. S.; Virk, R. K.; Tan, M. H.; Teo, A. K. J.; Hsu, L. Y.
title: A Viral Fragmentation Signature for SARS-CoV-2 in Clinical Samples Correlating with Contagiousness
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.11.21249265
sha: b41e473b33ccf5069fb4019fada8cba6a443d205
doc_id: 840033
cord_uid: y0slnjn0

The viral load of SARS-CoV-2 in clinical samples as measured by the primary diagnostic tool of RT-PCR is an imperfect readout for infection potential as most targeted assays designed for sensitivity, indiscriminately detect short and long RNA fragments, although infectivity is embodied only in the whole virus and its intact genome. Here, we used next-generation sequencing (NGS) to characterize 155 clinical samples and show sensitive and quantitative detection of viral RNA which confirmed subgenomic RNA in 57.6% of samples and provided a novel method to determine relative integrity of viral RNA in samples. The relative abundance of long fragments quantified as a viral fragmentation score was positively associated with viral load and inversely related to time from disease onset. An empirically determined score cut-off for presence of substantially fragmented RNA was able to identify 100% of samples collected after 8 days of illness with poor infection potential in line with current clinical understanding of infectiousness of SARS-CoV-2. The quantification of longer fragments in addition to existing short targets in an NGS or RT-PCR-based assay could provide a valuable readout of infection potential simultaneous to the detection of any fragments of SARS-CoV-2 RNA in test samples.

In March 2020, the World Health Organization (WHO) declared a pandemic of the coronavirus disease 2019 (COVID- 19) , an infection caused by severe acute respiratory . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. syndrome coronavirus 2 (SARS-CoV-2) 1 . By end of 2020, 82 million infections have been reported worldwide with 1.79 million deaths (https://coronavirus.jhu.edu). Diagnostic tools for detection of present and past infection of SARS-CoV-2 have been crucial for the management of this public health emergency, and include an array of molecular tests and immunoassays 2 . Direct detection of nucleic acids via reverse-transcription-polymerase chain reaction (RT-PCR) is the most widely deployed modality. Next-generation sequencing (NGS) is a related molecular method, and is characterized by the ability to identify polymorphisms and to define interrelatedness of virus strains 3, 4 , facilitated by the whole-genome interrogation of the virus.

Sensitive methods for detecting SARS-CoV-2 have been paramount in the identification and isolation of infected individuals and their close contacts, reducing viral transmission.

Releasing infected persons prematurely from isolation carries the risk of fuelling transmission, while prolonging isolation unnecessarily can adversely affect resource allocation and cause undue disruptions 5 . While RT-PCR assays are widely regarded as the most sensitive of diagnostic methods, the inability to distinguish intact viral RNApackaged in virions and able to cause onward transmissionfrom products of degradation of viral RNA ineffectual at further infection, has led to considerable debate on the dichotomous interpretation of RT-PCR results as positive/negative, and the in-depth analysis of the period of infectiousness 6, 7 . Positive detection of virus RNA does not prove presence of infectious virus, as persistent detection of viral RNA in samples has been reported up to 35 days from symptom onset [8] [9] [10] [11] [12] , and after resolution of clinical symptoms of both mild and severe disease [13] [14] [15] [16] . As large-scale vaccination is deployed across countries [17] [18] [19] , the uncertain impact of vaccination on potential contagiousness 20, 21 , further highlights the need for means to quantify contagiousness accurately.

The isolation of whole virions in cultured cells, in contrast to RNA fragments provides evidence of the isolate's replicative potential and more closely reflects the true infection potential 6 . Duration of live virus detection is much shorter than viral shedding and no live virus has been isolated in samples taken more than 8 days since symptom onset in immunocompetent patients 8, 11, 22 . In accordance with this, in a hamster model, transmissibility of SARS-CoV-2 correlated with detection of infectious virus by culture, but not by RT-PCR-positivity alone, and the communicable period was less than 6 days for inoculated donor animals 23 . Viral load dynamics also differ between upper respiratory tract samples, where highest viral loads were reported at the time of symptom onset or soon after at 3-5 days of illness followed by consistent decline, and in lower respiratory tract samples where peak viral load is in the second week of illness 7 . It is at present unclear if this dynamic is related to dynamic infection potential of transmitted material from each site.

Detection of subgenomic RNA (sgRNA) has been used as a proof of viral replication, which can only happen in infected cells, and declines over days 10-11 from infection 8 . sgRNA does not get packaged into virions therefore detection of sgRNA is indicative of actively infected cells in a sample, and complements the detection of infectious viral RNA packaged into virions. SgRNA have been detected in cultured cells and in limited clinical samples most commonly by NGS and by RT-PCR for specific sgRNA fusion products, but are not routinely studied 8, 24, 25 .

Prompted by the limitations of the most commonly used diagnostic device for SARS-CoV-2 for informing contagiousness, and by the urgent need to address this crucial parameter, in this study we employed whole-genome NGS with molecular barcoding and sequencing error-correction to characterize clinical samples collected from a cohort of migrant workers in Singapore. As a comprehensive tool with full genome targeting, NGS can inform presence of any SARS-CoV-2 RNA, the presence of sequence variants and sgRNA, and as we show for the first time, this method can also characterize the lengths of fragments of RNA in a sample. We go on to show that fragment lengths, characterized as a viral fragmentation score, are related to intactness of viral RNA, which is a prerequisite for infectiousness in the form of whole virus, and is correlated in with other clinical parameters of potential infectiousness such as viral load, sgRNA and duration of illness. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint 4

Samples used in this study were collected as part of a previous study conducted in a large cohort of migrant workers in Singapore, and evaluated and approved by the Director of Medical Services, Ministry of Health, under Singapore's Infectious Disease Act 26 . A total of 155 samples, corresponding to 48 individuals were analyzed by NGS. The samples included 37 nasopharyngeal (NP) swabs collected in 3 mL of viral transport medium, 60 self-nasal swabs, and 58 oropharyngeal saliva samples collected in 2 mL of viral RNA stabilization fluid (SAFER™ VTM, Lucence, Singapore). The majority of the cases (35 of 48, 72.9%) were symptomatic at the time of first sample collection, one case was presymptomatic at time of first sampling, and 12 cases (25%) were asymptomatic through the study. For asymptomatic cases, the day of the first diagnostic test was used to determine days since diagnosis. For 17 cases (35.4%), only a single sample was available for sequencing, and for the remaining 31 (64.5%) of cases, between 2 and 9 samples were studied. For 5 cases (10.41%), samples from different sites (NP, nasal swab or saliva) were available but from the same timepoint (not longitudinal). All samples had previously been characterized for presence of SARS-CoV-2 using an RT-PCR assay using primers and probes sequences from the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel 26, 27 , henceforth referred to as CDC RT-PCR assay. Samples were selected for NGS based on SARS-CoV-2 positivity at at least one of 2 or 3 timepoints of sample collection and relatively high viral loads as estimated by the RT-PCR assay. Archived extracted RNA from anonymized samples were used for this study.

Viral nucleic acid is extracted from the specimens (200 or 400 μl) using Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd., Taiwan) or QIAsymphony DSP Virus/Pathogen Kit (QIAGEN). For each sample, aliquots of extracted nucleic acid (RNA) was screened for presence of SARS-CoV-2 RNA using real-time reverse transcription-polymerase chain reaction (RT-PCR) targeting the N1 and N2 markers as specified by Centers for Disease Control and Prevention (CDC), and also processed for library preparation for NGS. Samples were processed in a College of American Pathologists (CAP) accredited and a Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory (Lucence).

Lower limit of detection (sensitivity) of the NGS method was determined using synthetic SARS-CoV-2 RNA spiked into pooled clinical matrix that tested negative for the virus by a RT-PCR method. For the analytical validation of NGS, synthetic SARS-CoV-2 RNA . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint was determined by comparing the genome coverage (%) resulting from confirmed negative samples (by RT-PCR), and no-template controls and that resulting from known positive samples (by RT-PCR).

A multiplex amplicon-based next generation sequencing (NGS) platform was developed to sequence the entire SARS-CoV-2 genome. Primers for 327 amplicons were designed to span the entire SARS-CoV-2 genome in tiled configuration, and alternately assigned to two separate primer pools (Pool 1 and Pool 2) to allow amplification of the whole genome while minimizing formation of short overlapping amplicons. Five primer pairs designed to target five different human housekeeping genes (TBP, MYC, LRP1, ITGB7, and HMBS) are used as control in both pools. Each forward primer additionally includes on the 5' end, a random 10 nucleotide sequence to serve as molecular barcode. Each designed primer was checked against published SARS CoV-2 genomes as of April 15 2020, and base degeneracy was incorporated when required to achieve coverage of >99% of Asian, USA, Europe and Chinese genomes published.

Based on the CDC RT-PCR results, extracted nucleic acid were diluted 10-fold for samples with cycle threshold (Ct) ≤20 or undiluted for samples with Ct>20, followed by reverse transcription using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) to generate complementary DNA (cDNA). A synthetic spike-in RNA control was added to the sample just before cDNA synthesis. The RNA control comprises a nucleotide sequence which is not found in a genome or a transcriptome of the virus, and is further not found in a genome or a transcriptome of a human, and is further not found in a genome or a transcriptome of a microorganism. Each cDNA was split into two reactions for target capture and enrichment of Pool 1 and Pool 2 using Platinum SuperFi II DNA Polymerase (Invitrogen, USA) under the following thermocycling conditions: Denaturation at 98 0 C for 30s, followed by 5 to 15 cycles (5 cycles for samples with Ct <15, 10 cycles for samples with Ct 15-30, 15 cycles for samples with Ct >30) of 98 0 C for 1 min, 60 0 C for 1 min, and 72 0 C for 1 min, with final extension at 72 0 C for 5 min. At the end of the reaction, excess primers were removed . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 6 by purification two times with 1.5x AMPure XP beads (Beckman Coulter,USA). Purified products were subjected to a final PCR to amplify targets and to complete the library with indexed sequencing adaptors for sequencing on the Illumina platform. Briefly, purified product was amplified with indexed P5 adapter sequence and indexed P7 adapter sequence using KAPA HiFi HotStart ReadyMix under the following thermocycling conditions:

Denaturation at 98 0 C for 45 s, followed by 18 cycles of 98 0 C for 15 s, 60 0 C for 30 s, and 72 0 C for 30 s, with a final extension at 72 0 C for 1 min. The amplified library was purified twice with 0.7x AMPure XP beads to remove non-specific products. The quality and quantity of the sequencing library is assessed using the 4200 Tapestation system (Agilent Technologies, USA) and KAPA Library Quantification Kit for Illumina® Platforms (Kapa Biosystems Inc., USA) respectively. Paired-end sequencing (2x151bp) of the final dualindexed libraries is performed on the Illumina platform as per manufacturer's instructions.

FASTQ files were processed using a custom pipeline. First, expected amplicons were identified and labeled in the FASTQ files based on the expected primer sequences in Read 1 and paired Read 2. Primer sequences and upstream molecular barcode sequences were trimmed using cutadapt, primer trimmed sequences were mapped to the reference genome SARS-CoV-2 reference genome (NCBI Reference Sequence: NC_045512.2) using bwamem. Molecular tag (or barcode) sequences were included in the trimmed "primer" sequences of read 1, and can be extracted given the unique structure of primer sequences in read 1. Barcode sequences were clustered based on sequence and amplicon identity, and consensus calling was done for each molecular tag (or barcode) cluster, by first performing global alignment among all associated reads using MAFFT. The consensus base in each aligned position was called by determining the majority representative base type, the percentage of which should be no less than an automatically determined threshold. The threshold is a function of the total number of reads for that barcode sequence. If no representative base could be called, the position was assigned N (as opposed to one of A, C, T, G). An overall quality score, of either 90 th percentile of all the quality values from the representative base type in that position (if a consensus base is found), or 10 th percentile of all quality values in that position (if no consensus bases is found) is assigned. The consensus reads are then written to a new FASTQ file.

First, consensus FASTQ files from two pool 1 and pool 2 were merged to create a single FASTQ file. Consensus FASTQ reads are mapped to the SARS-CoV-2 reference genome (NCBI Reference Sequence: NC_045512.2) using bwa-mem 28 . Samtools 29 was used to . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; 7 calculate depth per base and coverage metrics. Variant calling was performed on consensus BAM files using snippy and freebayes. For variants to be called, a minimum of 10x coverage is required. With molecular barcoding, the sequencing is error-free and can enable detection of quasispecies and increase confidence of variant calls due to the high quality of sequencing data. 

For each positive sample with sequencing data, SAMtools was used to capture insert sizes from alignment files with the following specifications: samtools view -f65 -F2048

SampleXYZ_consensus.bam | cut -f 1,4,9 > SampleXYZ_f65F2048.txt where f65 = filter in read paired, first in pair (Reads which are paired and insert sizes for first read in read pair and second in read in read pair will have same same insert size with "negative" length); F2048 = filter out reads with supplementary alignment (removes most subgenomic RNA reads which have part of reads with supplementary alignment and removes chimeric reads.

Finally inserts of size 70 to 1000 are retained to get representation of expected insert sizes as no insert is expected to be shorter than 72 bp (design of inserts) and remove extremely long inserts.

Binning of inserts was done based on the expected and observed insert sizes into 0-150 bp (short) and 151-350 bp (long) ranges. Short and long insert counts were determined for each . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint sample, representing short and long viral fragments, respectively. The viral fragmentation score is then derived as (number of fragments of size 151-350bp)/(number of fragments of size 0-150bp).

A multiplex three-target RT-PCR assay was designed for the simultaneous detection of two short targets of 70 bp each in the N gene region (in two separate detection channels), and one long amplicon of 240 bp in the S gene of the SARS-CoV-2 genome.

An internal housekeeping control target was included as fourth target in the multiplex reaction. Briefly, extracted RNA (5 μl) was mixed with the primers/probes for the multiplexed targets with Luna® Universal Probe One-Step RT-qPCR Kit (New England Biolabs, USA) and RT-PCR was performed using recommended protocol for the Luna master mix on a BioRad CFX96. Cycle threshold (Ct) values for each target were collected from respective channels and compared.

All datapoints are described individually with median and interquartile ranges, where appropriate. For comparison between groups, the Mann-Whitney unpaired t-test was used.

Regression analysis and curve fitting was done using Prism 8.0.1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint controls (NTC) were included to demonstrate the specific detection of SARS-CoV-2 in samples, unaffected by background rates of formation of non-specific products from highly multiplexed amplicon-based sequencing. The cut-off of 1.8% genome coverage correctly classified 100% of positive cases, while 2 samples called negative by RT-PCR were just above the cut-off at 2% and 3% genome coverage, respectively ( S1 ) and expected detection of variants from synthetic reference genome was also validated using this method (Fig. S2 ).

Comparative variant analysis on the SARS-CoV-2 genomes assembled from sequencing data was done for samples with >95% genome coverage (69 of 144, 47.9%) using the Wuhan/Hu-1/2019 genome as reference. Comparing samples originating from a single individual, samples from multiple timepoints, and those from differing sampling sites (upper respiratory tract or saliva), variants confidently detected (supported by >20x depth of coverage) were completely identical ( Fig. 2A ). This is contrast to a study in which throat swab and sputum from a patient sampled on the same day showed the presence of a unique variant in the throat swab, suggestive of independent replication in the two tissue sites 8 .

Among the variants identified, a stop codon in ORF8 gene c.175G>T p.Glu59* -28068G>T was observed in 6 samples coming from one individual, and 2 samples and one sample from two other individuals, respectively. Premature stop mutations in ORF8 have been reported among SARS-CoV-2 sequences in GenBank and GISAID initiative 33 .

As the identity of variants among multiple samples from the same case were conserved, a single representative sequence from each case was used for the phylogenetic tree construction. A total of 28 cases (58.3%) were analyzed, as they had at least one sample satisfying the >92% genome coverage lacking stretches of N's required for phylogenetic analysis 34 . All sequences were identical or highly similar to sequences reported in previous analyses of SARS-CoV-2 cases in Singapore, and belonged to Clade O by GISAID is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint nomenclature 35 , and lineage B.6 by PANGOLIN system of nomenclature 36 and with respect to each other the 28 cases fit into 3 main clusters (Fig. 2B) . One Case-28 which formed a single-case branch, harboured three unique variants M c.120C>T p.Ala40Ala -26642C>T and ORF3a c.377G>A p.Arg126Lys -25769G>A and orf1a c.6267G>T p.Glu2089Asp -6532G>T in four different samples collected for this case.

The panel of primers for whole-genome sequencing of SARS-CoV-2 was specifically designed to also capture subgenomic RNA (sgRNA) sequences involving the fusion of the 5' leader sequence (first 72 nt of the genome) of the SARS-CoV-2 genome with the 5' end of each mRNA coding sequence, called the "body". The tiled design of primer pairs and inclusion of the primer targeting the 5' leader in both primer pools allows the capture of sequences corresponding to canonical sgRNA containing a consensus core sequence 24 .

The relative abundance of each sgRNA was normalized by the mean genome depth of coverage of a sample to make comparisons across samples and sgRNA species. Among individuals with symptoms, sgRNA was found be relatively more abundant when found in URT (NP and nasopharyngeal) samples relative to saliva samples (unmatched) and was mostly detectable between -1 to 7 days since symptom onset (Fig. 3A) . In both URT samples and saliva, the three most abundant sgRNA species were N, M genes and ORF3a.

ORF10 was detected in only one of 68 evaluable positive URT samples, and was not detected in any of 59 positive saliva samples from symptomatic cases. This is in accordance with previous findings which found almost no subgenomic reads corresponding to ORF10 24, 25, 31 . Presence of sgRNA is considered an indicator of active viral replication 8,11 with more frequent detection in samples collected <8 days after symptom onset 11 and has been reported to persist up to 22 days 37 after onset of clinical symptoms Among samples in the present study, the persistence of sgRNA detection was observed in samples from 8-12 days since symptom onset and up to day 13 in saliva (Fig. 3A) . Samples from asymptomatic cases also had prevalent sgRNA detection in URT samples 0-3 days since diagnosis (Fig.   3B ). In contrast to URT samples, in saliva from asymptomatic cases, sgRNA could be detected in up to 5-6 days since diagnosis. No sgRNA was detected at 8 days since diagnosis. Individually assessed, detection rate of sgRNA progressively decreased over time is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021.

3C). These results suggest that sgRNA is frequently detected in multiple samples types containing a minimal viral load related to Ct value in both symptomatic and asymptomatic cases. However, there is no relation between the abundance of sgRNA and Ct; following an approximate dichotomy of detection around Ct 28.7.

We observed that one of the consequences of tiling multiple primer pairs (in subsequence) to capture the entire known target template of SARS-CoV-2 in a highly multiplexed PCRbased NGS method, was the capture of longer inserts in addition to the inserts expected to be formed from amplicons of length 130-178 bp for which primer pairs were originally designed (Fig. S4A) . The origin of the longer inserts was the formation of amplicons between a given forward primer and a reverse primer that is 1-, 2-, 3-, 4-and so on-displaced in the subsequence of primer pairs in the pool of primers (Fig. S4B ). We reasoned that the more degraded the viral RNA template, the more the capture of short inserts (representing short fragments) would be favoured, due to the unavailability of intact RNA template for longer amplicons to form (Fig. S4C) . Analysis of the sequencing data for the distribution of insert lengths per sample, showed that 2 to 3 distinct ranges of insert lengths could be captured per sample, and the number of sequencing reads supporting inserts in each insert length group could vary substantially between samples (Fig. 4A) . Based on the dominance of inserts of lengths either 70-150 bp or 220-350 bp in sequencing data (and not other longer insert length groups), we chose these two insert length groups for further study and refer to them as "short" and "long" fragments, respectively. The cumulative number of short and long fragments (all reads mapping to SARS-CoV-2 from all potential primer combinations across the targeted genome) for samples were determined. It is noted that the sizes of the amplicons for N1 and N2 targets from the CDC RT-PCR assay initially used to characterize the samples are 72 bp and 67 bp, allowing sensitive detection of even very small fragments of virus RNA. It follows that such an RT-PCR assay would not be able to distinguish between long and short fragments that may exist in a given sample, but would give a cumulative readout comprising all fragments. In 144 samples positive for SARS-CoV-2 by the CDC RT-PCR assay, the sequencing read counts for long and short fragments were each correlated with Ct value as expected, diminishing as the Ct value increased or presumed viral load decreased. However, the longer fragments had a steeper change in abundance relative to Ct value, become disproportionately fewer relative to short fragments in samples with low viral load reflected by later Ct values (Fig. 4B) . We hypothesize, given a mass of viral RNA (a mix of intact and degraded RNA), measurable as a Ct value by an assay like the CDC RT-PCR assay with very short amplicons, that at later Ct values, previously long fragments have been converted to short fragments due to degradation of viral RNA, and contribute in turn to the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ;

12 observed read counts for short fragments which continue to maintain a relatively higher count from this contribution. Consequently, degradation of viral RNA more rapidly leads to the diminishing read counts for long fragments observed at late Ct values. This suggests that counting long fragments or the relative distribution of long to short fragments would provide a more accurate read-out for presence, if any, of intact viral RNA in samples.

We devised a viral fragmentation score, VFS (long to short fragment count ratio) to capture this variability in distribution of fragment lengths. VFS showed a moderate correlation with Ct (R 2 = 0.65 in NP and nasal swabs, and R 2 = 0.74 in saliva), suggesting relative abundances of long and short fragments within a sample are not captured fully by its Ct value, despite detection of long fragments diminishing with increasing Ct values (Fig. 4C) . For 5 samples sequencing libraries were repeated from RNA extracts and VFS were shown to be within reproducible range for the same sample (Table S1) (Fig. 4C, Fig. S5 ). This experiment shows that factors besides total viral RNA amount measured by a Ct value (with short PCR amplicons) determine the VFS, which depends on the presence of long fragments, more of which is likely to be present in a sample with more intact. This is supported by the wide variation in VFS that was observed in clinical samples, which was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint

Overall, these results support the presence of a wide range of fragmentation profiles in clinical samples which is readily detectable by NGS.

As our NGS method was able to quantify relative abundances of short and long fragments representing less and more intact virus, respectively, next we determined if VFS was related to other clinical correlates of infectivity. This is particularly relevant as it is well-recognised that RT-PCR positivity alone, particularly from a test designed for short targets, does not translate to viable virus with infection potential 5, 6 . We have already shown that VFS is moderately correlated with Ct value (Fig. 4C) , which in itself is considered a proxy for infectious potential of SARS-CoV-2 in clinical samples based on the culturability of virus isolates 8, 11, 12, 22, 38, 39 although with widely differing Ct cut-offs. In multiple studies, no live virus has been culturable after eight days in non-immunocompromised patients 2,10,14 . The typical clinical profile of the symptomatic cases in our study was immunocompetent with presentation of mild to moderate respiratory symptoms. Compared directly, VFS and days since symptom onset was not strongly correlated in both URT and saliva samples over the full duration of the symptom onset (days -1 to day 14) (Fig. 5A and 5B) . However, transposing a VFS derived from a sample with known integrity i.e. synthetic RNA (refer to days did not recover live virus 9, 11, 22 . Among asymptomatic cases, 25 (96%) of 26 samples had low VFS below 0.382 cut-off, from 0 to 8 days from diagnosis, suggesting that viral RNA from most asymptomatic cases is fragmented (Fig. 5C ). For one case, VFS 3.36 of saliva sample collected on the day of diagnosis was matched with URT samples (NP and nasal swabs) from the same case with VFS of 0.79 and 0.14, suggesting a less fragmented SARS-CoV-2 RNA in saliva even at same timepoint. Overall, VFS differed significantly between samples collected ≤8 days from symptoms and those after 8 days for cases with information on symptom onset (Fig. 5D, left) , but it was difficult to find a time measure that trended with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint 14 VFS for asymptomatic cases (Fig. 5D, right) . For cases with multiple longitudinal samples, VFS were tracked with respect to time from symptom onset and were generally observed to be higher early between days -1 to 6 and generally decreased with time reaching levels similar to those seen asymptomatic cases through the course of the asymptomatic infection (Fig. 5E ).

We observed no linear correlation between increasing VFS and total sgRNA abundance ( Fig. 6A) , but there was a significant difference in VFS of samples with any sgRNA compared to those with none, showing a dichotomous distribution (p<0.0001) (Fig. 6B) . The Ct (70bp-240bp) VFI was correlated with the VFS (R 2 =0.79, p<0.0001) (Fig. 7A, right) . Over days since symptom onset, the VFI became more negative, indicating the increasingly greater abundance of short 70 bp amplicon, likely due to increasing fragmentation of viral RNA over clinical course of the disease (Fig. 7B ).

We used next-generation sequencing (NGS) to characterize clinical samples related to the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint Detection of sgRNA has been used as a proof of viral replication in infected cells and decline over days 10-11 from infection 8 . sgRNA detection outlasted successful virus culture and was a poor predictor of successful virus culture 14 , or showed moderate agreement with virus culture, and was detected in 18 (81.8%) of 22 specimens collected <8 days after symptom onset and in 1 (9.1%) of 11 specimens collected ≥9 days after symptom onset 11 . Due to the prolonged detection of sgRNA in clinical samples including up to 22 days since start of illness, sgRNA may not be a marker of active replication but remain detectable in clinical samples due their stability 37 .

In this study, abundant sgRNA was detected in clinical samples including prolonged detection in a saliva sample taken 13 days from illness onset from a symptomatic case. In samples with high viral loads, sgRNA was consistently detected, but became undetectable in ~75% of samples with low viral loads (Ct≥28.67), suggesting that both viral load and sgRNA stability account for its detection. This study, to our knowledge, is the first one to demonstrate direct sgRNA detection in samples from immunocompetent asymptomatic individuals 43 although at lower levels than symptomatic cases, in line with the non-zero but reduced transmission potential of asymptomatic carriers 44 .

It is increasingly becoming apparent that positive detection of virus RNA by RT-PCR is unrelated to presence of infectious virus, as viral RNA shedding can persist even after resolution of clinical symptoms of both mild and severe disease [8] [9] [10] [11] [12] [13] [14] [15] [16] . While more ill patients have generally longer detection of RNA, persistent positivity by PCR is seen in patients with mild illness as well as in asymptomatic cases 5 . A better measure of infectiousness is the culture of live virus from clinical specimens as successful virus growth is reliant on the presence of intact whole virions with complete RNA genomes. By this measure, samples taken more than 8 days since symptom onset in immunocompetent patients, do not have infectious virus as no live virus could be cultured from them 8, 11, 22 . In immunocompromised patients or those with severe illness, live virus could be isolated up to 14 days 12 , 20 days 14 and much longer in severely immunocompromised patients 45 . Ability to culture live virus has been shown to be similar in asymptomatic and symptomatic indivduals [46] [47] [48] . Some studies have correlated viral loads measured by Ct value with ability to culture live virus 8,11,14,22,38,46 , and no viral growth was reported based on a Ct value cut-off (varying between >24 and ≥35) 22, 38, 48 . Intriguingly, a number of studies have reported limited correlation between Ct value (or viral load) and success of virus isolation 49, 50 . Samples with low Ct values (Ct<23), constituted 28.6% of samples with unsuccessful viral culture 50 , and conversely, samples with low viral loads (Ct >35) could harbor viable virus 49, 50 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint

The observation that not all samples with high viral loads generate live virus, suggest that factors other than viral genome copies are important. The topmost factor would be viral integrity, whether for a small or large viral load. Only the full-length intact viral RNA would represent the virus fragment that is capable of infection. It is understood that the processing of sample in the laboratory (extraction, enzymatic reactions) would lead to some degree of fragmentation, and the use of primer-limited amplicons would artificially limit fragment lengths but relative to a sample with highly fragmented viral RNA, a sample with intact viral RNA would contain more long fragments relative to short fragments.

In this work we have shown for the first time that NGS data can not only provide total viral RNA abundance information, it can also characterize the viral RNA fragments by length. This was possible due to combination of consensus read counting (related to the original copy numbers of virus RNA in a sample undergoing library preparation) and the tiled configuration of the primer panel which could capture long fragments, if present. In other words, the more intact or full-length RNA that is present in a sample, the more long fragments would be captured by the method. The relative abundances of long and short fragments was converted to a viral fragmentation score (VFS), representing the relative integrity of the virus RNA in the sample and was shown to be related to the viral load measured as Ct value by an RT-PCR assay. It is important to highlight that the CDC RT-PCR assay targets particularly short amplicons of about 70 bp, which means it would accurately detect intact RNA when present, but would continue give an abundant signal even when largely fragmented RNA was present in a sample. At early Ct values (representing abundant viral load), the relative abundance of long fragments were as much as 100-185 times more than short fragments (very high viral fragmentation score) and could not have resulted simply as a result of the specific sequencing method.

To further address if the observed relative abundances were simply a function of the copy number of template subject to sequencing, irrespective of its starting length, we showed using synthetic SARS-CoV-2 RNA, that for relatively intact RNA template molecules the VFS remains constant even over 500-fold reduction in starting copy numbers. An empirically determined cut-off from synthetic RNA applied to clinical samples was able to separate all samples collected >8 days since illness onset as having predominantly fragmented RNA.

This correlated very well with the failure to culture live virus from clinical samples collected after 8-9 days of illness in immunocompetent patients 8, 11, 22, 38, 47, 51 . Conversely, based on the cut-off, about 50% of case with VFS <0.382 (hence lesser intact RNA) were collected ≤ 8 days from symptom onset. This fraction mirrors those observed previous studied with about 29%-42% of samples high viral inferred from low Ct or from ≤8 days did not recover live virus 9, 11, 22 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.11.21249265 doi: medRxiv preprint Another variable to consider is the sample type. Viral load and duration of positivity tends to be greater in lower respiratory tract samples (sputum) compared to throat and nasal swabs 5, 52 . Accordingly, prolonged ability to culture virus has been reported for samples from severely ill patients with mostly lower respiratory tract samples 14 , compared to the success rate in upper respiratory tract samples 46 . In the present study, upper respiratory tract samples (nasopharyngeal and nasal swabs) and oropharyngeal saliva samples were compared. Oropharyngeal saliva contains secretion of the salivary glands mixed with sputum from lower respiratory tract 53 , hence is more akin to lower respiratory tract samples. In line with this, we observed higher VFS (more long fragments) in saliva samples on average compared to URT samples.

One study has looked at the potential of RT-PCR assays to determine the integrity of viral is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ;

integrity to virus culture is necessary to further these findings. There are important limitations to this study. The use of the exact cut-off of VFS to categorize samples into clinical groups may not universally apply. Nonetheless, the basic premise of the argument that more intact virus would reflect in more longer fragments in a clinical sample would universally apply. As the study's main conclusions are based on NGS, with some comparison to RT-PCR results, without evidence from virus culture studies it cannot be ruled out that some of the observed infectivity measures are correlated and result from a feature of the specific NGS method.

In conclusion, we have applied NGS to comprehensively characterize longitudinal samples collected from different sites. NGS is an enabling tool that provides sequence-related information for which it is primarily designed, and also information from size and length dimensions. Based on this, we identify fragment length differences among clinical samples which are correlated to clinical features of infectiousness of SARS-CoV-2, quantification of which could be incorporated as relevant and straightforward measure to determine infection potential.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. (C) VFI from RT-PCR assay shows a correlation with days since diagnosis and for 7 samples not plotted due to non-detection of 240 bp, the days from diagnosis were ≥ 7.

Coronavirus disease 2019: What we know

Considerations for diagnostic COVID-19 tests

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Viral cultures for COVID-19 infectious potential assessment -a systematic review

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe

Virological assessment of hospitalized patients with COVID-2019

Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds

Viable SARS-CoV-2 in various specimens from COVID-19 patients

SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease

Viral dynamics and immune correlates of COVID-19 disease severity

Prolonged virus shedding even after seroconversion in a patient with COVID-19

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

Duration of Viral Shedding of Discharged Patients With Severe COVID-19

Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19

China began large-scale vaccination of priority groups to fight against the novel coronavirus

Putin Tells Russia To Begin Large-Scale Vaccination For Coronavirus

US poised for large-scale vaccination as global death toll hits 1.6m

Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines

SARS-CoV-2 Vaccination -An Ounce (Actually, Much Less) of Prevention

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

The Architecture of SARS-CoV-2 Transcriptome

Direct RNA sequencing and early evolution of SARS-CoV-2

Validation of Saliva and Self-Administered Nasal Swabs for

Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes

Aligning sequence reads, clone sequences and assembly contigs with

The Sequence Alignment/Map format and SAMtools

Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus

The coding capacity of SARS-CoV-2

Nextstrain: real-time tracking of pathogen evolution

Evolutionary dynamics of the SARS-CoV-2 ORF8 accessory gene

Building and analyzing a SARS-CoV-2 consensus genome

Phylogenetic Clustering by Linear Integer Programming (PhyCLIP)

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19

A rapid, low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing

Highly sensitive and full-genome interrogation of SARS-CoV-2 using multiplexed PCR enrichment followed by next-generation sequencing

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada e20200030

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Investigation of SARS-CoV-2 outbreaks in six care homes in London

Persistent SARS-CoV-2 replication in severe

Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review

Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England

What can we expect from first-generation COVID-19 vaccines?

Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021

We would like to thank all the medical laboratory technologists at Lucence service laboratory for their hard work and support which made this study possible.

The authors declare no competing interests..